STAAR Surgical names Andrew Pilon. Stifel targets STAAR Surgical stock at USD 31

Published on 10/18/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STAAR Surgical appointed Pilon on October 8, 2026. Stifel set a USD 31 target for STAAR Surgical stock and second-quarter revenue reached USD 93.5 million.

Appointments and valuation context

STAAR Surgical appointed Andrew Pilon on October 8, 2026.
Stifel raised its target from USD 28 to USD 31 on September 29, 2026.
STAAR Surgical had a USD 1.1 billion market capitalization as of October 16, 2026.

STAA, US8523123052, Illustration mit AI erstellt.

STAAR Surgical (ISIN US8523123052) appointed Andrew Pilon as vice president of business development on October 8, 2026, according to Business Wire. The role puts strategic partnerships, licensing opportunities and product expansion at the center of the latest management move.

Three events shape the story

STAAR Surgical's recent chronology shows a company combining capital allocation with expansion plans. On September 24, 2026, the board authorized a share repurchase program of up to USD 50.0 million, while the company reported USD 181.5 million in cash, cash equivalents and investments available for sale as of July 3, 2026, according to Business Wire. On September 29, 2026, Stifel upgraded the stock from Hold to Buy and raised its target from USD 28 to USD 31, as reported by Investing.com. The October 8 appointment was the latest of the three events.

What does the target change mean?

The analyst action followed second-quarter 2026 revenue of USD 93.5 million, above the USD 90.17 million consensus cited by Investing.com. Adjusted earnings per share came in at USD 0.16 versus the USD 0.22 estimate, creating a mixed operating signal despite the revenue beat. China sales reached USD 52.3 million, up 10.0 percent sequentially, while Stifel's 2028 base case projected 11.0 percent annual sales growth from 2026 to 2028 against an 8.0 percent consensus estimate.

Next reporting date is November 4

MarketBeat lists November 4, 2026 as the estimated date for STAAR Surgical's third-quarter 2026 results, after the market close. The page also gives a consensus revenue estimate of USD 78.74 million and adjusted earnings per share of USD 0.0503 for that quarter.

Valuation follows the operating test

STAAR Surgical had a market capitalization of USD 1.1 billion and a 52-week range of USD 15.59 to USD 35.87 as of October 16, 2026. The company focuses on implantable phakic intraocular lenses, with its EVO ICL products marketed in more than 85 countries and more than 4 million lenses sold to date, according to the company's investor-relations page.

The next results will test whether second-quarter revenue growth can continue while profitability improves. For investors, the contrast between above-consensus revenue and below-consensus adjusted earnings per share is the central operating question.